July 30,2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eugenio A. Cefali

Serial No.: 08/960,557

Filed: October 31, 1997

For: Methods for Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics

Examiner: Channavajjala, Lakshmi Sarada

Group Art Unit: 1611

Attorney Docket No.: SD-50003USP6

Certificate of Mailing or Transmission (37 CFR §1.8(a)) I hereby certify that this correspondence is being electronically transmitted with the USPTO Web-base electronic filing system, facsimile transmitted or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit

Mull d

Power of Attorney and Change of Correspondence Address

Dear Sir:

Please recognize as Attorneys in this case, all practitioners associated with customer number 23492, with authority to prosecute this application and to transact all business in the Patent Office connected therewith.

It is requested that all correspondence be directed to Paul D. Yasger whose address is:

Abbott Laboratories
Dept. 0377 Bldg. AP6A-1
100 Abbott Park Road
Abbott Park, IL 60064-6008

Attached hereto, please find a memo delegating Paul D. Yasger the authority to sign any documents on behalf of KOS Pharmaceuticals, Inc. and/or KOS Life Sciences, Inc.

Respectfully submitted, Eugenic A. Cefali

Paul D. Yasger

Registration No. 37,477 Attorney for Applicants

ABBOTT LABORATORIES
Customer Number 23492

Telephone: (847) 937-6364 Facsimile: (847) 938-2623



DATE:

FROM:

Tom Freyman

TO:

Rachel Polster Paul Yasger

SUBJECT:

Delegation of signature authority regarding patents and patent

applications filed in the name of Kos Pharmaceuticals, Inc. and

Kos Life Sciences, Inc.

I hereby delegate Paul D. Yasger, DVP and Associate General Counsel, Patents and Trademarks, the authority to sign any documents related to the preparation, prosecution and maintenance of patent applications and resulting patents that were filed in the name of Kos Pharmaceuticals, Inc. or Kos Life Sciences, Inc.

If Paul D. Yasger vacates his position as DVP and Associate General Counsel, Patents and Trademarks, the signature authority will no longer exist and this document shall be null and void.

Approved:

Tom Freyman

President

Kos Pharmaceuticals, Inc.

Kos Life Sciences, Inc.